Treatment patterns and costs for anti-TNFα biologic therapy in patients with psoriatic arthritis

Table 3 Summary of treatment modification for anti-TNFα biologic therapy in patients with PsA for the 3-year follow-up

	Patients With Only First-line Anti-TNFα Biologic Therapy (n = 881)^a	Patients With Second-line Anti-TNFα Biologic Therapy (n = 72)^a	Patients with Third-line or Greater of Anti-TNFα Biologic Therapy (n = 37)^a
First-line, n (%)
Anti-TNFα increase	6 (0.7)	0	0
Anti-TNFα decrease	7 (0.8)	0	1 (2.7)
DMARD add-on	74 (8.4)	8 (11.1)	7 (18.9)
DMARD removal	59 (6.7)	12 (16.7)	2 (5.4)
DMARD drug change^b	27 (3.1)	2 (2.8)	2 (5.4)
DMARD dose increase	2 (0.2)	1 (1.4)	0
DMARD dose decrease	2 (0.2)	0	0
Any of the above	177 (19.8)	23 (31.9)	12 (32.4)
Second-line, n (%)
Anti-TNFα increase	N/A	2 (2.8)	0
Anti-TNFα decrease	N/A	2 (2.8)	0
DMARD add-on	N/A	10 (13.9)	0
DMARD removal	N/A	4 (5.6)	8 (21.6)
DMARD drug change^b	N/A	3 (4.2)	2 (5.4)
DMARD dose increase	N/A	0	0
DMARD dose decrease	N/A	0	0
Any of the above	N/A	21 (29.2)	10 (27.0)
Third-line or greater, n (%)
Anti-TNFα increase	N/A	N/A	0
Anti-TNFα decrease	N/A	N/A	0
DMARD add-on	N/A	N/A	8 (21.6)
DMARD removal	N/A	N/A	4 (10.8)
DMARD change^b	N/A	N/A	0
DMARD dose increase	N/A	N/A	0
DMARD dose decrease	N/A	N/A	0
Any of the above	N/A	N/A	12 (32.4)

DMARD disease-modifying antirheumatic drug, TNFα tumor necrosis factor-α
^aAnti-TNFα biologic therapy refers to the following anti-TNFα agents: etanercept, adalimumab, infliximab, and golimumab
^bFirst-line DMARD change was the most recent DMARD in 60-day prior to index anti-TNFα biologic treatment and second- and third-line or greater DMARD change was the most recent DMARD in the previous line

ISSN: 1471-2474